GS vs PFE: Which Is the Better Buy?
Side-by-side comparison of The Goldman Sachs Group, Inc. and Pfizer Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-09-25.
The Goldman Sachs Group, Inc. · Financial Services
$923.29
+25.9% upside to fair value
Med Conviction
Grade C
High Quality
VS
Pfizer Inc. · Healthcare
$27.64
+12.0% upside to fair value
Med Conviction
Grade B
QuantHub Verdict
GS has more upside to fair value
(+25.9%).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
GS |
PFE |
| Current Price |
$923.29 |
$27.64 |
| Fair Value Estimate |
$1,162.79 |
$30.94 |
| Upside to Fair Value |
+25.9%
|
+12.0%
|
| Market Cap |
$272.4B |
$157.5B |
| Forward P/E |
—
|
—
|
| EV / EBITDA |
26.3x
|
17.4x
|
| Price / Sales |
2.3x
|
2.5x
|
| Price / FCF |
—
|
14.3x
|
| Revenue Growth YoY |
+22.9%
|
+2.6%
|
| Gross Margin |
57.3%
|
71.3%
|
| Operating Margin |
24.8%
|
25.1%
|
| Return on Equity |
17.0%
|
4.9%
|
| Dividend Yield |
1.95% |
6.22% |
| FCF Yield |
—
|
6.97%
|
| Analyst Consensus |
Hold
|
Hold
|
Investment Thesis
Goldman Sachs is a global financial services firm operating four divisions: Investment Banking, Global Markets, Asset Management, and Consumer & Wealth Management, with 46,200 full-time employees and a market cap of $272.38 billion at a current price of $923.29. The business quality is high because of its leading franchise in advisory, underwriting, and trading, evidenced by a 17.0% ROE, a 57.3% …
Pfizer is a global biopharmaceutical leader with a portfolio spanning cardiovascular, oncology, vaccines, immunology, and rare disease, anchored by Eliquis, the Prevnar family, Vyndaqel, Ibrance, Xtandi, Comirnaty, and Paxlovid, and supported by roughly 75,000 employees and a contract manufacturing division. Business quality is medium rather than high: TTM gross margin of 71.3% and TTM operating …
Accumulation Zones
| Metric |
GS |
PFE |
| Zone Low |
$872.09 |
$23.21 |
| Zone High |
$988.37 |
$26.30 |
| In Buy Zone? |
Yes
|
No
|